Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development July 16, 2025
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants July 1, 2025
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium June 10, 2025
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia May 13, 2025
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision May 12, 2025
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial April 9, 2025
